Krebs Biochemicals & Industries Ltd.
KREBSBIO · ISIN: INE268B01013
Krebs Biochemicals & Industries Ltd. is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE268B01013.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Krebs Biochemicals & Industries Ltd. - growth of ₹100
Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-3.77%
3M
+7.98%
6M
-2.92%
1Y
-18.35%
3Y CAGR
-5.64%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Krebs Biochemicals & Industries Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
Not available for this stock yet.
Shareholding Pattern
Not available for this stock yet.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-10-01 | BULK | 742 |
| 2026-10-01 | BULK | 1,20,268 |
Frequently asked questions
What is Krebs Biochemicals & Industries Ltd.'s 1-year and 3-year return?
Krebs Biochemicals & Industries Ltd.'s 1-year price return is -18.35%. Its 3-year CAGR (annualized return) is -5.64%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Krebs Biochemicals & Industries Ltd.'s latest financial performance?
Krebs Biochemicals & Industries Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹25 Cr, with a TTM profit after tax of ₹-14 Cr and an EBITDA margin of null%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹-6.54.
Has Krebs Biochemicals & Industries Ltd. seen any recent bulk or block deals?
Yes, as of 2026-10-01 - the most recent recorded deal was a BULK on 2026-10-01 for 742 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns